Formulary
Etodolac: Indications, Dosing, Side Effects and Interactions
Etodolac clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Etodolac: Indications, Dosing, Side Effects and Interactions
Etodolac clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Pain and inflammation in rheumatoid arthritis and osteoarthritis**
- **Adult** (By Mouth Using Modified-Release Medicines): 600 mg once daily.
Cautions
Allergic disorders; cardiac impairment (NSAIDs may impair renal function); cerebrovascular disease; coagulation defects; connective-tissue disorders; dehydration (risk of renal impairment); elderly (risk of serious side-effects and fatalities); heart failure; history of gastro-intestinal disorders (e.g. ulcerative colitis, Crohn's disease); ischaemic heart disease; may mask symptoms of infection; peripheral arterial disease; risk factors for cardiovascular events; uncontrolled hypertension
Contraindications
Active gastro-intestinal bleeding; active gastro-intestinal ulceration; history of gastro-intestinal bleeding related to previous NSAID therapy; history of gastro-intestinal perforation related to previous NSAID therapy; history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes); history of recurrent gastro-intestinal ulceration (two or more distinct episodes); severe heart failure
Side effects
Frequency not known Agranulocytosis; angioedema; aplastic anaemia; asthenia; asthma; bilirubinuria; bronchospasm; chills; confusion; constipation; Crohn's disease aggravated; depression; diarrhoea; dizziness; drowsiness; dyspnoea; fever; gastrointestinal discomfort; gastrointestinal disorders; haemolytic anaemia; haemorrhage; hallucination; headache; heart failure; hepatic disorders; hypersensitivity; hypertension; insomnia; malaise; meningitis aseptic (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); nausea; nephritic syndrome; nephritis tubulointerstitial; nephrotoxicity; nervousness; neutropenia; oedema; optic neuritis; oral ulceration; palpitations; pancreatitis; paraesthesia; photosensitivity reaction; renal failure (more common in patients with pre-existing renal impairment); severe cutaneous adverse reactions (SCARs); skin reactions; thrombocytopenia; tinnitus; tremor; urinary disorders; vasculitis; vertigo; visual impairment; vomiting Side-effects, further information For information about cardiovascular and gastrointestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs
Interactions
**Other interactions (14):**
- Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4) Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4).
- Since etodolac is extensively protein-bound, it may be necessary to modify the dosage of other highly protein-bound drugs.
- Bilirubin tests can give a false positive result due to the presence of phenolic metabolites of etodolac in the urine.
- Mifepristone: NSAIDs should not be used for 8 - 12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.
- Other analgesics including cyclooxygenase-2 selective inhibitor: Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects (see section 4.4).
- Quinolone antibiotics: Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics.
Pregnancy
Important safety information For etodolac MHRA/CHM advice: NSAIDs: potential risks following prolonged use after 20 weeks of pregnancy (June 2023) See Non-steroidal anti-inflammatory drugs .
Breast feeding
Use with caution during breast-feeding. Manufacturer advises avoid.
Hepatic impairment
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment.
Renal impairment
In general, for NSAIDs the MHRA advises to avoid where possible; if necessary, use with caution (risk of fluid retention and further renal impairment, including renal failure). For etodolac , avoid in severe impairment. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Etodolac in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

